RNA-electroporated T cells for cancer immunotherapy.
RNA-electroporated T cells for cancer immunotherapy.
复制标题
DOI：
10.1080/2162402x.2020.1792625
复制
发表时间：
2020-10-07
期刊：
影响因子：
7.2
通讯作者：
Mitchell DA
中科院分区：
文献类型：
--
作者：
Pohl-Guimarães F;Hoang-Minh LB;Mitchell DA
过继性 T 细胞疗法已被证明可有效对抗血液系统恶性肿瘤，并在临床前研究和临床试验中证明对多种实体瘤有效。尽管如此，针对实体瘤的抗肿瘤反应仍然有限，这凸显了提高这种疗法有效性的必要性。人们已经探索用 RNA 对 T 细胞进行基因修饰，以增强 T 细胞抗原特异性、效应器功能和向肿瘤部位的迁移，从而增强抗肿瘤免疫力。这篇综述描述了 RNA 电穿孔 T 细胞修饰的基本原理，并概述了它们在治疗血液恶性肿瘤和实体瘤的临床前和临床研究中的应用。
Adoptive T cell therapy has proven effective against hematologic malignancies and demonstrated efficacy against a variety of solid tumors in preclinical studies and clinical trials. Nonetheless, antitumor responses against solid tumors remain modest, highlighting the need to enhance the effectiveness of this therapy. Genetic modification of T cells with RNA has been explored to enhance T-cell antigen specificity, effector function, and migration to tumor sites, thereby potentiating antitumor immunity. This review describes the rationale for RNA-electroporated T cell modifications and provides an overview of their applications in preclinical and clinical investigations for the treatment of hematologic malignancies and solid tumors.